Biotech, healthtech, medtech – why ‘convergence’ is a trap nobody admits to falling into

Everyone in healthcare innovation loves talking about convergence. Biotech companies add software. Medtech firms develop companion apps. Healthtech startups claim they’re doing both. Venture capitalists nod sagely about the “blurring boundaries” between sectors.

It’s all bullshit.

Convergence isn’t innovation, it’s confusion masquerading as progress. And it’s costing companies millions in wasted capital, years in regulatory purgatory, and countless failed pitches to investors who can’t figure out what the hell you actually do.​

Healthcare technology sectors increasingly overlap: AI diagnostics, companion diagnostics, and personalized medicine platforms defy simple categorization

The problem isn’t that these sectors are converging. The problem is that everyone pretends the distinctions don’t matter when they matter more than ever for regulation, funding, market strategy, and survival.​

The definitions nobody can agree on (and why that’s a disaster)

Ask ten healthcare investors to define “healthtech” and you’ll get twelve different answers.

Biotech supposedly means using living organisms or biological systems to develop products—primarily drugs and therapies targeting specific diseases. Simple enough, right?​

Except when biotech companies develop diagnostic devices. Or when they create software platforms for drug discovery. Or when they engineer bacteria to produce materials. Are those still “biotech”?

Medtech refers to medical devices, physical hardware used to diagnose, treat, or monitor health conditions. Pacemakers. Surgical robots. MRI scanners. Tangible stuff you can touch.​

Until you realize that most modern medical devices are 70% software. The FDA classifies “Software as a Medical Device” (SaMD) as medtech, but it behaves nothing like traditional devices in development, regulation, or business model.​

Healthtech is the vaguest category of all, supposedly covering digital health solutions, wellness apps, telemedicine platforms, and health IT systems. Anything with “health” and “technology” that isn’t clearly the other two gets dumped here.​

The FDA’s own guidance acknowledges this mess. Their digital health terminology includes: mHealth, health information technology, wearable devices, telehealth, telemedicine, personalized medicine, software as a medical device, and about fifteen other subcategories that nobody uses consistently.​

Biotech, medtech, and healthtech differ dramatically: biotech requires $500M-$2.5B over 10-15 years while healthtech can launch with $5M-$100M in 6-18 months

Why venture capitalists actually care

Here’s what investors won’t tell you: they don’t fund “convergent” companies. They fund biotech OR medtech OR healthtech, and if you can’t clearly articulate which one you are, you’re unfundable.​

Biotech investment requires a completely different mindset than medtech. You’re looking at 10-15 year development timelines, $500 million to $2.5 billion in capital requirements, and binary outcomes where clinical trial failure means total loss.​

VCs investing in biotech expect massive potential returns, think $10+ billion market caps, because the risk is astronomical. They need deep scientific expertise to evaluate drug candidates, understand the regulatory pathway from IND to NDA approval, and assess clinical trial design.​

Medtech investment operates on different physics. Development timelines compress to 3-7 years, capital requirements drop to $50-500 million, and risk profiles skew toward engineering and manufacturing challenges rather than scientific uncertainty.​

Medtech VCs focus on clinical evidence, reimbursement pathways, and competitive positioning. They’re comfortable with Class II device submissions but nervous about Class III devices requiring full Premarket Approval. The expertise required is fundamentally different from drug development.​

Healthtech investment lives in yet another universe. Six to eighteen month development cycles. $5-100 million capital requirements. Market adoption risk trumping everything else.​

Healthtech investors evaluate user engagement metrics, SaaS economics, regulatory avoidance strategies, and network effects. Many healthtech products face minimal FDA oversight, which sounds great until you realize it also means minimal competitive moats.​

When you claim to be “convergent,” investors literally don’t know which criteria to apply. Are you a 10-year bet or a 3-year flip? Do they need pharma expertise or software skills on the board? What’s the regulatory strategy—drug approval or device clearance or nothing?

The result – you fall between funding categories and get nobody’s money.​

The regulatory nightmare that kills convergent products

One product. Seven regulators. That’s not hyperbole, that’s the actual nightmare facing companies building at the intersection of these sectors.​

Convergence creates regulatory nightmares: one AI insulin pump faces seven different regulatory frameworks across FDA, HIPAA, EU MDR, and AI Act

Let’s walk through a real example: an AI-powered insulin pump that analyzes your genetic data to personalize dosing recommendations.​

The insulin delivery mechanism makes it a medical device requiring FDA Center for Devices and Radiological Health (CDRH) oversight—probably Class III requiring full Premarket Approval given it’s life-sustaining.​

The AI algorithm that makes dosing decisions triggers Software as a Medical Device classification under FDA guidance, requiring algorithm validation, cybersecurity assessment, and ongoing monitoring.​

The genetic data analysis component potentially invokes FDA Center for Drug Evaluation and Research (CDER) jurisdiction if it’s guiding therapeutic decisions based on pharmacogenomics.​

The collection and storage of health data brings HIPAA compliance requirements, privacy rules, and security standards that have nothing to do with medical efficacy.​

If you’re selling in Europe, add the Medical Device Regulation (MDR) requiring CE marking, clinical evaluation reports, and post-market surveillance.​

The AI Act in the EU classifies AI systems used in healthcare as “high risk,” triggering additional conformity assessment requirements, data quality standards, and human oversight obligations.​

And if you make any therapeutic or diagnostic claims in marketing materials, the FTC gets involved with consumer protection enforcement.​

Each regulator has different timelines, requirements, expertise, and review processes. The FDA CDRH review team has zero incentive to coordinate with the HIPAA compliance office. The EU MDR notified bodies don’t talk to FDA reviewers.​

Companies spend 3-5 years just navigating regulatory pathways that should theoretically run in parallel but actually create an incomprehensible maze of sequential approvals, conflicting requirements, and regulatory gaps where nobody has clear jurisdiction.​

The cost of regulatory compliance for convergent products can hit $50-150 million before you sell a single unit. Traditional medtech companies spend $31 million on average to bring a device to market. Traditional biotech spends $1.4 billion on drug development. Convergent products often fall in between but with way more complexity.​

The classification chaos that makes everything worse

Nobody knows how to classify convergent products, including the regulators themselves.​

The FDA’s medical device classification system uses a risk-based approach with three categories: Class I (low risk), Class II (moderate risk), Class III (high risk).​

But that system was designed for dumb hardware. Scalpels, bandages, x-ray machines. Things that don’t update themselves wirelessly or learn from patient data or integrate with other systems.​

Software throws everything into chaos. The FDA published guidance on Software as a Medical Device in 2013, updated it in 2017, issued additional guidance in 2019, and companies STILL don’t know how to classify their products.​

Is a fitness tracker a medical device? Not if it just counts steps. But what if it detects atrial fibrillation? Suddenly it’s Class II requiring 510(k) clearance. Unless the algorithm is just “informational”—then maybe it’s not a device at all.​

Is an AI diagnostic tool a medical device? Depends whether it makes autonomous decisions or just assists physicians. Except the line between “assist” and “decide” is philosophical rather than technical. And the FDA’s position keeps evolving.​

The Digital Therapeutics Alliance created their own classification system with eight categories trying to bring clarity to digital health products. It hasn’t helped. Now there are just MORE competing taxonomies.​

Europe’s Medical Device Regulation uses entirely different classification criteria than the FDA, creating products that are Class II in the US but Class IIa in Europe, or vice versa.​

The result: companies spend 18 months just figuring out WHAT they are before they can figure out how to get approved.​

Why “digital therapeutics” is the worst offender

Digital therapeutics might be the most toxic example of convergence confusion.​

These products claim to “prevent, manage, or treat a medical disorder or disease” using software and behavioral interventions. They want the clinical credibility of pharmaceuticals combined with the development speed of software.​

The problem? They’re neither fish nor fowl, and everyone knows it.​

Digital therapeutics companies try to get prescription status so insurance will reimburse them like drugs. But they don’t go through drug trials. They want FDA clearance as medical devices, but they don’t want the post-market surveillance requirements. They claim clinical evidence from studies that wouldn’t pass FDA scrutiny for actual therapeutics.​

The reimbursement nightmare is spectacular. Insurance companies don’t know whether to classify DTx as medical devices, drugs, or software. Most end up in the “durable medical equipment” category with payment rates that make the business model impossible.​

Clinical evidence standards remain vague. What counts as proof of efficacy for a cognitive behavioral therapy app? Traditional drug trials require double-blind, placebo-controlled studies with thousands of patients. DTx companies run 100-person pilot studies and claim victory.​

Regulatory pathways keep shifting. FDA created the Pre-Cert Program specifically for digital health, then essentially abandoned it. The agency issued draft guidance on Clinical Decision Support software in 2019, then revised it in 2022, and companies still don’t have clarity.​

The convergence trap here is obvious: digital therapeutics wanted the benefits of multiple categories (clinical credibility + software agility + device reimbursement) while avoiding the costs (pharma-grade trials + FDA scrutiny + ongoing surveillance).​

Instead, they got the worst of everything: regulatory uncertainty, payment denials, and investor skepticism.​

The funding gap that destroys companies in the middle

There’s a valley of death for every convergent company, and it’s not where you think.​

Traditional seed funding ($1-5 million) works great for pure healthtech software. Angel investors, accelerators, and early-stage VCs can evaluate products, assess market fit, and understand business models.​

Traditional Series A funding ($10-30 million) works for medtech companies with clear regulatory pathways and clinical evidence plans. Medical device VCs understand the playbook.​

Traditional Series B+ funding ($50+ million) works for biotech with validated science and IND-enabling studies complete. Pharma VCs know these deals.​

Convergent companies need $5-15 million for their first real funding round—too much for software investors, too little for biotech specialists, too weird for medtech VCs.​

They’ve spent 18 months figuring out their regulatory strategy. They’ve built a prototype that crosses multiple categories. They have promising early data but not FDA clearance. They’re in the exact space where nobody has a mandate to invest.​

Traditional healthtech VCs look at the regulatory complexity and run. Traditional medtech VCs look at the software component and feel uncomfortable. Traditional biotech VCs wonder why you’re not just developing a drug.​

The SVH Medtech Convergence Fund exists specifically because this gap is so pronounced. But one fund can’t fix an entire ecosystem problem.​

Bridge financing becomes impossible. Down rounds become common. Companies dilute themselves to death trying to fit into funding categories that weren’t designed for what they’re building.​

The market positioning disaster nobody discusses

Marketing convergent products is a special kind of hell.​

If you emphasize the biotech angle, hospitals think you’re a pharma company and route you to their pharmacy committees. Those committees expect drug-level pricing, clinical trial data, and formulary processes. Your device gets rejected for “not being a drug”.​

If you emphasize the medtech angle, purchasing departments expect device pricing, capex budgets, and surgeon champions. Your AI component gets ignored. Your genetic insights get dismissed as “just another feature”.​

If you emphasize the healthtech angle, you get routed to the IT department. They evaluate you like enterprise software—security compliance, integration requirements, user training. Your clinical value proposition gets lost in vendor management processes.​

Hospital procurement has separate pathways for drugs (pharmacy), devices (capital equipment), and software (IT). There’s no pathway for “all three”.​

Insurance reimbursement uses different codes and payment structures for drugs (prescription), devices (procedure codes), and software (basically nothing). Products that span categories often end up with zero reimbursement because they don’t fit any existing payment model.​

Sales teams require completely different expertise. Pharma sales reps detail physicians with clinical studies and drug info. Device reps demo products in operating rooms. Software salespeople pitch ROI to administrators. You need all three—at triple the cost.​

The messaging confusion kills deals. Are you selling therapeutic outcomes, operational efficiency, or diagnostic accuracy? If you try to sell all three, you sell nothing. Buyers’ brains literally can’t process multi-category value propositions.​

The talent problem that nobody wants to admit

Building convergent products requires teams with skills that don’t exist in nature.​

You need molecular biologists who understand protein engineering AND software engineers who can build machine learning pipelines AND hardware engineers who can design medical devices AND regulatory experts who understand FDA drug AND device pathways.​

These people don’t exist. And if they did, they’d be so expensive you couldn’t afford them.​

Traditional biotech companies hire PhDs in chemistry, biology, and medicine. They have regulatory affairs teams specializing in FDA drug development. Their clinical teams understand clinical trial design for pharmaceuticals.​

Traditional medtech companies employ mechanical engineers, electrical engineers, and materials scientists. Their regulatory specialists know device classification and 510(k) submissions. Their clinical teams design device trials.​

Traditional healthtech companies hire software engineers, UX designers, and data scientists. They have minimal regulatory overhead. Their go-to-market teams focus on enterprise software sales.​

Convergent companies need ALL of these skills simultaneously. The salary budget becomes absurd. The management challenge of coordinating such diverse expertise becomes impossible.​

Recruiting is torture. Biotech candidates think you’re not “real” science. Medtech candidates worry about career progression. Software engineers hate regulatory constraints. Nobody wants to be the first hire in a category they don’t understand.​

Why the big players avoid convergence like poison

Pharma giants could easily build convergent products. They have the capital, expertise, and market access. They don’t, because convergence destroys their business model.​

Pharmaceutical companies optimize for blockbuster drugs generating $1+ billion annually for 10-20 years. Their R&D, regulatory, sales, and reimbursement systems all support this model.​

A digital component that improves drug efficacy sounds great until you realize it complicates clinical trials, adds regulatory requirements, creates software maintenance obligations, and confuses payers who can’t figure out how to reimburse a “drug-device combination”.​

Medical device companies similarly avoid true convergence. They might add a mobile app to a glucose monitor, but that’s not convergence, it’s feature expansion. True convergence would mean fundamentally rethinking their product architecture, regulatory strategy, and business model.​

Big tech companies flirt with healthcare convergence, then back away when they realize the regulatory constraints. Google, Apple, Microsoft all have health initiatives that carefully stay on the “wellness” side of the line to avoid FDA oversight.​

The M&A market for convergent startups is terrible. Pharma acquirers want drugs. Medtech acquirers want devices. Software acquirers want SaaS platforms. A company that’s all three finds no natural buyer.​

The future probably isn’t convergence, it’s specialization

Here’s the unpopular truth: convergence might be a temporary phenomenon rather than the future.​

As regulatory frameworks mature, they’re likely to force greater specialization rather than enable broader convergence. The EU AI Act specifically creates detailed requirements for different use cases. FDA guidance increasingly separates different types of digital health products.​

Reimbursement systems are hardening category distinctions rather than blurring them. New payment models for digital therapeutics create separate tracks from traditional drugs and devices.​

Investment categories are crystallizing. Funds like SVH Medtech Convergence Fund exist, but they’re exceptions proving the rule that most capital flows into clearly defined categories.​

The successful models might end up being partnerships rather than convergence. Pharma companies partnering with software firms. Device companies licensing AI algorithms. Clear roles, clear responsibilities, clear regulatory pathways.​

Innovation will likely happen within categories rather than across them. Better drugs through improved biology. Smarter devices through better engineering. More effective software through superior algorithms. Each optimizing within existing frameworks rather than fighting them.​

The companies succeeding right now are those that picked a lane. Are you a drug company using some software tools? Fine, go through drug approval. Are you a device company with AI? Great, follow device pathways. Are you software with wellness claims? Perfect, avoid FDA entirely.​

The companies failing are those still claiming to be everything, unable to answer basic questions about what regulatory pathway they’re pursuing or what type of investor should fund them.​

So what should you actually do?

Pick one category. Seriously. Just one.​

Figure out what your core value proposition is. If you’re fundamentally changing how a disease is treated through molecular intervention, you’re biotech. If you’re improving clinical outcomes through a physical device, you’re medtech. If you’re changing behavior or optimizing workflows through software, you’re healthtech.​

Optimize everything for that category. Regulatory strategy, fundraising approach, team composition, go-to-market plan, exit strategy. Stop trying to be all things to all people.​

Use other categories as supporting elements, not defining characteristics. Your drug can have a companion app—that doesn’t make you “convergent.” Your device can use AI, that doesn’t make you a software company. Your software can impact health, that doesn’t make you a medical device.​

Communicate clearly what you are. Investors, regulators, customers, and partners need to immediately understand your primary category. If they’re confused after your pitch, you’ve already lost.​

Accept that this might mean leaving opportunities on the table. You might have great ideas for features that cross categories. Build them later, after you’ve succeeded in your primary category. Or don’t build them at all.​

Because convergence isn’t the future of healthcare innovation. Clarity is. And the sooner you accept that, the better your chances of surviving long enough to prove it.